Treatment protocol determines the efficacy of clindamycin in acute murine toxoplasmosis

International Journal of Antimicrobial Agents

Volumn 11, Issue 2, 1999, Pages 145-149

  Nikolic T ^a   Djurkovic Djakovic O ^a   Bobic B ^a   Nikolic A ^a   Babic D ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Clindamycin; Murine model; Toxoplasma gondii; Treatment protocol

Indexed keywords

CLINDAMYCIN;

ANIMAL MODEL; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TOXOPLASMA GONDII; TOXOPLASMOSIS;

EID: 0345291186     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(98)00064-8     Document Type: Article

References (16)

1. Katlama C. Diagnosis and treatment of toxoplasmosis of the CNS in patients with AIDS. CNS Drugs 1996;5:331-43.
2. Remington JS, McLeod R, Desmonts G. Toxoplasmosis. In: Remington JS, Klein JO, editors. Infectious Diseases of the Fetus and Newborn Infant. Philadelphia: WB Saunders, 1995.
3. Pfefferkorn ER, Nothnagel RF, Borotz SE. Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant. Antimicrob Agents Chemother 1992;36:1091-6.
4. Fichera ME, Bhopale MK, Roos DS. In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob Agents Chemother 1995;39:1530-7.
5. McMaster PRB, Powers KG, Finerty JF, Lunde MN. The effect of two chlorinated lincomycin analogues against acute toxoplasmosis in mice. Am J Trop Med Hyg 1973;22:14-7.
6. Araujo FG, Remington JS. Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrob Agents Chemother 1974;5:647-51.
7. Thiermann E, Apt W, Atias A, Lorca M, Olguin J. A comparative study of some combined treatment regimens in acute toxoplasmosis in mice. Am J Trop Med Hyg 1978;27:747-50.
8. Hofflin JM, Remington JS. Clindamycin in a murine model of toxoplasmic encephalitis. Antimicrob Agents Chemother 1987;31:492-6.
9. Garin JP, Paillard B. Toxoplasmose expérimentale de la souris. Activité comparée de: clindamycine, midécamycine, josamycine, spiramycine, pyriméthamine-sulfadoxine, et triméthoprime-sulfaméthoxazole. Ann Pédiatr 1984;31:841-5.
10. Piketty C, Dérouin F, Rouveix B, Pocidalo J. In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice. Antimicrob Agents Chemother 1990;34:1467-7142.
11. Filice GA, Pomeroy C. Effect of clindamycin on pneumonia from reactivation of Toxoplasma gondii infection in mice. Antimicrob Agents Chemother 1991;35:780-2.
12. Araujo FG, Slifer T, Remington JS. Rifabutin is active in murine models of toxoplasmosis. Antimicrob Agents Chemother 1994;38:570-5.
13. Vuković D, Djurković-Djaković O, Kovacević S, et al. Effect of clindamycin in a model of acute murine toxoplasmosis. Clin Microbiol Infect 1997;3:89-94.
14. Eyles DE, Coleman N. Notes on the treatment of acute experimental toxoplasmosis of the mouse with chlortetracycline and tetracycline. Antibiot Chemother 1956;4:988-91.
15. Vuković D, Todorović V, Bobić B, Nikolić A, Djurković-Djaković O. Clindamycin at human therapeutical doses is efficacious in acute murine toxoplasmosis. Iugoslav Physiol Pharmacol Acta 1996;32:243-7.
16. Tomavo S, Boothroyd JC. Interconnection between organellar functions, development and drug resistance in the protozoan parasite, Toxoplasma gondii. Int J Parasitol 1995;25:1293-9.